Amicus Therapeutics, Inc. (FOLD)
Current
- (-)
After Hours
Rating Performance
Rating Return
-17.26% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-26.35% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-26.35% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-48.07% vs
Rating Accuracy
0.0% (0 of 2*)
FV Performance
FV Accuracy
2 Hits (28.57% Hit Rate)
FV Avg. Distance
+21.31%
FV Accuracy
2 Hits (15.38% Hit Rate)
FV Avg. Distance
+27.93%
FV Accuracy
8 Hits (32.0% Hit Rate)
FV Avg. Distance
+28.15%
FV Accuracy
19 Hits (38.78% Hit Rate)
FV Avg. Distance
+16.08%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
John Francis Crowley
Employees
584
Industry
Endocrinology and Metabolism Biopharmaceuticals
Sector
Healthcare
Headquarters
Cranbury
Exchange
NASDAQ
Website
http://www.amicusrx.comSummary Stats
Market Cap
2.22B
Revenue
318M
Net Income
-270M
EPS
-$0.97
Price-to-Earnings
-8.13
Price-to-Book
9.29
Debt-to-Equity
2.47
News
Analyst Ratings
Price targets projected by 10 analysts
High
$31.00
Average
$23.20
Low
$19.00
Ratings calculated by 10 analysts
Buy
8
Hold
2
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Missed by -$0.05
-$0.30 -20.0%
-0.25
-0.25
Down 20%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--